Novorex is a small-molecule drug developer that leverages protein three-dimensional structure analysis and molecular computation to develop small-molecule drugs. The company combines an advanced AI-driven drug development platform with expertise in fragment-based drug discovery (FBDD) to enable seamless drug development. Novorex focuses on oncology and neurological disease targets and emphasizes using AI to identify early candidate molecules and validate their binding to target proteins. The firm says its approach can discover potential candidates against traditionally undruggable targets and accelerates discovery while reducing the time costs associated with traditional high-throughput screening (HTS). Novorex announced it has raised $8.8751 million in a Series A financing. The company highlights its AI and FBDD capabilities as core to its continued drug discovery efforts.

Total raised

$9M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2023